Literature DB >> 15619135

Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise.

Malcolm Brown1, Andrew Bjorksten, Ivan Medved, Michael McKenna.   

Abstract

OBJECTIVE: We aimed to determine the pharmacokinetics (PK) of N-acetylcysteine (NAC) at rest and during exercise when given by continuous intravenous infusion intended to maintain relatively constant plasma concentrations.
METHODS: Plasma concentrations of NAC were measured in 24 healthy male subjects during and after a two-stage intravenous infusion designed to provide constant NAC concentrations during cycling exercise, including intense exercise to fatigue.
RESULTS: A three-compartment, open PK model was the best fit using population PK analysis with NONMEM. Whole-body clearance (CL) was 0.58 l kg(-1) h(-1) (95% CI 0.44-0.72) for reduced NAC (NACR) and 0.16 (0.13-0.20) l kg(-1) h(-1) for total NAC (NACT). The central volume of distribution (V1) was 0.064 (0.008-0.12) l kg(-1) for NACR and 0.037 (0.02-0.06) l kg(-1) for NACT. Exercise was a significant covariate in the model, resulting in a 25 and 23% reduction in CL of NACR and NACT, respectively. V1 in our subjects was smaller than expected, resulting in higher-than-anticipated initial concentrations of NAC. Despite these findings, the incidence of adverse effects attributable to NAC was minimal without using prophylactic or concomitant drug therapy.
CONCLUSIONS: NAC can be given to healthy exercising men by intravenous infusion and to the plasma concentrations seen in this study with minimal adverse effects due to the drug. The PK parameters of NAC at rest in volunteers are consistent with previously reported values and are significantly altered by vigorous cycling exercise.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619135     DOI: 10.1007/s00228-004-0862-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

Authors:  B Olsson; M Johansson; J Gabrielsson; P Bolme
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  General theory for rapidly establishing steady state drug concentrations using two consecutive constant rate intravenous infusions.

Authors:  D P Vaughan; G T Tucker
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage.

Authors:  L F Prescott; J W Donovan; D R Jarvie; A T Proudfoot
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Splanchnic blood flow and hepatic glucose production in exercising humans: role of renin-angiotensin system.

Authors:  R Bergeron; M Kjaer; L Simonsen; J Bülow; D Skovgaard; K Howlett; H Galbo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-12       Impact factor: 3.619

5.  Attenuated hepatosplanchnic uptake of lactate during intense exercise in humans.

Authors:  H B Nielsen; J O Clemmesen; C Skak; P Ott; N H Secher
Journal:  J Appl Physiol (1985)       Date:  2002-04

6.  N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals.

Authors:  I Medved; M J Brown; A R Bjorksten; K T Murphy; A C Petersen; S Sostaric; X Gong; M J McKenna
Journal:  J Appl Physiol (1985)       Date:  2004-06-11

7.  Adverse reactions to acetylcysteine and effects of overdose.

Authors:  T G Mant; J H Tempowski; G N Volans; J C Talbot
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-28

8.  N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans.

Authors:  I Medved; M J Brown; A R Bjorksten; J A Leppik; S Sostaric; M J McKenna
Journal:  J Appl Physiol (1985)       Date:  2002-12-20

9.  Pharmacokinetics of N-acetylcysteine in man.

Authors:  L Borgström; B Kågedal; O Paulsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  N-acetylcysteine inhibits muscle fatigue in humans.

Authors:  M B Reid; D S Stokić; S M Koch; F A Khawli; A A Leis
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more
  15 in total

1.  Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

Authors:  Thomas D Nolin; Rosemary Ouseph; Jonathan Himmelfarb; M Elizabeth McMenamin; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  The design and analysis of parallel experiments to produce structurally identifiable models.

Authors:  S Y Amy Cheung; James W T Yates; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-09       Impact factor: 2.745

3.  Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Authors:  Marc R Mansour; Casie Reed; Amy R Eisenberg; Jen-Chieh Tseng; Jean-Claude Twizere; Sarah Daakour; Akinori Yoda; Scott J Rodig; Noa Tal; Chen Shochat; Alla Berezovskaya; Daniel J DeAngelo; Stephen E Sallan; David M Weinstock; Shai Izraeli; Andrew L Kung; Alex Kentsis; A Thomas Look
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

4.  Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning.

Authors:  Anselm Wong; Cornelia Landersdorfer; Andis Graudins
Journal:  Eur J Clin Pharmacol       Date:  2017-06-17       Impact factor: 2.953

5.  In response to: "Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning".

Authors:  Elie Harmouche; Mary Ann Howland; Mark K Su
Journal:  Eur J Clin Pharmacol       Date:  2017-11-20       Impact factor: 2.953

6.  Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors.

Authors:  Alexander J Neuwelt; Tam Nguyen; Y Jeffrey Wu; Andrew M Donson; Rajeev Vibhakar; Sujatha Venkatamaran; Vladimir Amani; Edward A Neuwelt; Louis B Rapkin; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-08-17       Impact factor: 3.167

Review 7.  Performance and Side Effects of Supplementation with N-Acetylcysteine: A Systematic Review and Meta-Analysis.

Authors:  Kate Rhodes; Andrea Braakhuis
Journal:  Sports Med       Date:  2017-08       Impact factor: 11.136

8.  Lifelong physical activity prevents an age-related reduction in arterial and skeletal muscle nitric oxide bioavailability in humans.

Authors:  Michael Nyberg; James R Blackwell; Rasmus Damsgaard; Andrew M Jones; Ylva Hellsten; Stefan P Mortensen
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

Review 9.  Evidence for the changing regimens of acetylcysteine.

Authors:  Angela L Chiew; Geoffrey K Isbister; Stephen B Duffull; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-11-23       Impact factor: 4.335

Review 10.  N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.

Authors:  Hesamoddin Hosseinjani; Azadeh Moghaddas; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.